Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High Dose (2.0mg) Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

NCT01334879 is registered in ClinicalTrials.gov with The New York Eye Cancer Center as lead sponsor.

NCT NCT01334879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01334879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High Dose (2.0mg) Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
Lead sponsor
The New York Eye Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
November 30, 2012
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

radiation retinopathy